Abstract:<h2 class="section-title u-h3 u-margin-l-top u-margin-xs-bottom">Summary</h2><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Background</h3><p>Depression is usually managed in primary care, but most antidepressant trials are of patients from secondary care mental health services, with eligibility criteria based on diagnosis and severity of depressive symptoms. Antidepressants are now used in a much wider group of people than in previous regulatory trials. We investigated the clinical effectiveness of sertraline in patients in primary care with depressive symptoms ranging from mild to severe and tested the role of severity and duration in treatment response.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>The PANDA study was a pragmatic, multicentre, double-blind, placebo-controlled randomised trial of patients from 179 primary care surgeries in four UK cities (Bristol, Liverpool, London, and York). We included patients aged 18 to 74 years who had depressive symptoms of any severity or duration in the past 2 years, where there was clinical uncertainty about the benefit of an antidepressant. This strategy was designed to improve the generalisability of our sample to current use of antidepressants within primary care. Patients were randomly assigned (1:1) with a remote computer-generated code to sertraline or placebo, and were stratified by severity, duration, and site with random block length. Patients received one capsule (sertraline 50 mg or placebo orally) daily for one week then two capsules daily for up to 11 weeks, consistent with evidence on optimal dosages for efficacy and acceptability. The primary outcome was depressive symptoms 6 weeks after randomisation, measured by Patient Health Questionnaire, 9-item version (PHQ-9) scores. Secondary outcomes at 2, 6 and 12 weeks were depressive symptoms and remission (PHQ-9 and Beck Depression Inventory-II), generalised anxiety symptoms (Generalised Anxiety Disorder Assessment 7-item version), mental and physical health-related quality of life (12-item Short-Form Health Survey), and self-reported improvement. All analyses compared groups as randomised (intention-to-treat). The study is registered with EudraCT, 2013-003440-22 (protocol number 13/0413; version 6.1) and ISRCTN, ISRCTN84544741, and is closed to new participants.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Findings</h3><p>Between Jan 1, 2015, and Aug 31, 2017, we recruited and randomly assigned 655 patients—326 (50%) to sertraline and 329 (50%) to placebo. Two patients in the sertraline group did not complete a substantial proportion of the baseline assessment and were excluded, leaving 653 patients in total. Due to attrition, primary outcome analyses were of 550 patients (266 in the sertraline group and 284 in the placebo group; 85% follow-up that did not differ by treatment allocation). We found no evidence that sertraline led to a clinically meaningful reduction in depressive symptoms at 6 weeks. The mean 6-week PHQ-9 score was 7·98 (SD 5·63) in the sertraline group and 8·76 (5·86) in the placebo group (adjusted proportional difference 0·95, 95% CI 0·85–1·07; p=0·41). However, for secondary outcomes, we found evidence that sertraline led to reduced anxiety symptoms, better mental (but not physical) health-related quality of life, and self-reported improvements in mental health. We observed weak evidence that depressive symptoms were reduced by sertraline at 12 weeks. We recorded seven adverse events—four for sertraline and three for placebo, and adverse events did not differ by treatment allocation. Three adverse events were classified as serious—two in the sertraline group and one in the placebo group. One serious adverse event in the sertraline group was classified as possibly related to study medication.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Interpretation</h3><p>Sertraline is unlikely to reduce depressive symptoms within 6 weeks in primary care but we observed improvements in anxiety, quality of life, and self-rated mental health, which are likely to be clinically important. Our findings support the prescription of SSRI antidepressants in a wider group of participants than previously thought, including those with mild to moderate symptoms who do not meet diagnostic criteria for depression or generalised anxiety disorder.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Funding</h3><p>National Institute for Health Research.</p>

Population Pharmacokinetics of Sertraline in Psychiatric and Substance Use Disorders

Population Pharmacokinetic Modeling to Inform Sertraline Dosing Optimization in Patients with Depression

Population pharmacokinetic approach to guide personalized sertraline treatment in Chinese patients

Impact of CYP2C19 genotype on sertraline exposure in 1200 Scandinavian patients

A population pharmacokinetic model for sertraline in women during the perinatal period—A contribution from the ConcePTION project

Possible Sertraline-Induced Extrapyramidal Adverse Effects in an Adolescent.

Review of sertraline and its clinical applications in psychiatric disorders

Analysis of prescriptions of three selective serotonin reuptake inhibitors from a perspective of metabolic interactions

Clinical Observation of Sertraline in Treatment of Child Emotional Disorder

Sex-controlled differences in sertraline and citalopram efficacies in major depressive disorder: a randomized, double-blind trial

Low-Dose Ziprasidone in Combination with Sertraline for First-Episode Drug-Naïve Patients with Schizophrenia: a Randomized Controlled Trial

Sertraline, 1S,4S-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-naphthylamine, a new uptake inhibitor with selectivity for serotonin.

Selection of the optimal dose of sertraline for depression: A dose-response meta-analysis of randomized controlled trials.

The clinical effectiveness of sertraline in primary care and the role of depression severity and duration (PANDA): a pragmatic, double-blind, placebo-controlled randomised trial

Comparison of Efficacy and Safety Between Low-Dose Ziprasidone in Combination With Sertraline and Ziprasidone Monotherapy for Treatment-Resistant Patients With Acute Exacerbation Schizophrenia: A Randomized Controlled Trial

Machine Learning‐Based Prediction of Escitalopram and Sertraline Side Effects with Pharmacokinetic Data in Children and Adolescents

[Population Pharmacokinetics Research of Clozapine in Chinese Schizophrenic Patients].

The association between serotonin-related gene polymorphisms and susceptibility and early sertraline response in patients with panic disorder

A pooled analysis of the efficacy of sertraline in women, with a focus on those of childbearing age

Preparation of Sertraline-Loaded Chitosan Nanoparticles and the Pharmacokinetics Studies

An improved dosage regimen of sertraline hydrochloride in the treatment for premature ejaculation: an 8-week, single-blind, randomized controlled study followed by a 4-week, open-label extension study.